Abstract
To investigate the effect of p33ING1 on wild-type p53 gene therapy, T.Tn human esophageal carcinoma cells were stably transfected with p33ING1 cDNA. Infection with Ad-p53 (recombinant adenovirus containing wild-type p53) into p33-transfected cells reduced cell viability, while infection with empty vector had little effect. This reduced viability was shown to be due to apoptotic cell death by the TUNEL (terminal deoxynucleotidyl transferase-mediated nick end-labeling) assay. Following infection with Ad-p53, levels of p53 were similar in p33-expressing cells and in the parental line. However, levels of p21 and Mdm2 were elevated in p33-transfected cells. Nonetheless, this enhanced expression of Mdm2 appeared to be ineffective in downregulating p53. Transient transfection with mutant Mdm2 prior to Ad-p53 infection provided a significant protection as compared with cells transfected with wild-type Mdm2. These results imply a synergistic effect between p33 and p53 in the induction of apoptosis of human esophageal carcinoma cells. A role for Mdm2 in this synergism is suggested.
This is a preview of subscription content, access via your institution
Access options
Similar content being viewed by others
Abbreviations
- wtp53:
-
wild type p53
- Ad-p53:
-
recombinant wild-type p53 adenoviral vector
- Ad-LZ:
-
recombinant LacZ adenoviral vector
- CMV:
-
cytomegalovirus
- MOI:
-
multiplicity of infection
- MTT:
-
3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide
- PBS:
-
phosphate-buffered saline
- TUNEL:
-
terminal deoxynucleotidyl transferase-mediated nick end-labeling
- BaP:
-
benzo[a]pyrene
- ALLN:
-
acetyl-Leu-Leu-norleucinal
References
Asada M, Yamada T, Ichijo H, Delia D, Miyazono K, Fukumuro K, Mizutani S . 1999 EMBO J. 18: 1223–1234
Aschele C, Sobrero A, Faderan MA, Bertino JR . 1992 Cancer Res. 52: 1855–1864
Baker SJ, Markowitz S, Fearon ER, Willson JKV, Vogelstein B . 1990 Science 249: 912–915
Barak Y, Oren M . 1992 EMBO J. 11: 2115–2121
Bargou BRC, Wagener C, Bommert K, Arnold W, Daniel PT, Mapara MY, Grinstein E, Royer HD, Dörken B . 1996 J. Exp. Med. 183: 1205–1213
Bennett WP, Hollstein MC, Metcalf RA, Welsh JA, He A, Zhu S, Kusters I, Resau JH, Trump BF, Lane DP, Harris CC . 1992 Cancer Res. 52: 6092–6097
Bissonnette N, Hunting DJ . 1998 Oncogene 16: 3461–3469
Buckbinder L, Talbott R, Velasco-Miguel L, Takenaka I, Faha B, Seizinger BR, Kley N . 1995 Nature 377: 646–649
Chang Y-C, Nakajima H, Illenye S, Lee YS, Honjo N, Makiyama T, Fujiwara I, Mizuta N, Sawai K, Saida K, Mitsui Y, Heintz NH, Magae J . 2000 Oncogene 19: 4713–4720
Chen J, Wu X, Lin J, Levine AJ . 1996 Mol. Cell. Biol. 16: 2445–2452
Chen PL, Chen Y, Bookstein R, Lee WH . 1990 Science 250: 1576–1580
Chen L, Matsubara N, Yoshino T, Nagasaka T, Hoshizima N, Shirakawa Y, Naomoto Y, Isozaki H, Riabowol K, Tanaka N . 2001 Cancer Res. 61: 4345–4349
Cheung Jr K-J, Mitchell D, Lin P, Li G . 2001 Cancer Res. 61: 4974–4977
DeGregori J, Leone G, Miron A, Jakoi L, Nevins JR . 1997 Proc. Natl. Acad. Sci. USA 94: 7245–7250
Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ, Vogelstein B, Friend SH . 1990 Mol. Cell. Biol. 10: 5772–5781
Dirks PB, Rutka JT, Hubbard SL, Mondal S, Hamel PA . 1998 Oncogene 17: 867–876
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer E, Kinzler KW, Vogelstein B . 1993 Cell 75: 817–825
Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M . 1989 Proc. Natl. Acad. Sci. USA 86: 8763–8767
Fakharzadeh SS, Trusko SP, George DL . 1991 EMBO J. 10: 1565–1569
Finlay CA, Hinds PW, Levine AJ . 1989 Cell 57: 1083–1093
Garkavtsev I, Grigorian IA, Ossovskaya VS, Chernov MV, Chumakov PM, Gudkov AV . 1998 Nature 391: 295–298
Garkavtsev I, Kazarov A, Gudkov A, Riabowol K . 1996 Nat. Genet. 14: 415–420
Gorczyca W, Bruno S, Darzynkiewicz RJ, Gong J, Darzynkiewicz Z . 1992 Int. J. Oncol. 1: 639–648
Gunduz M, Ouchida M, Fukushima K, Hanafusa H, Etani T, Nishioka S, Nishizaki K, Shimizu K . 2000 Cancer Res. 60: 3143–3146
Gu Y, Turch CW, Morgan DO . 1993 Nature 366: 707–710
Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ . 1993 Cell 75: 805–816
Haupt Y, Barak Y, Oren M . 1996 EMBO J. 15: 1596–1606
Haupt Y, Maya R, Kazaz A, Oren M . 1997 Nature 387: 296–299
Helbing CC, Veillette C, Riabowol K, Johnston RN, Garkavtsev I . 1997 Cancer Res. 57: 1255–1258
Hiwasa T, Sakiyama S . 1996 Cancer Lett. 99: 87–91
Hiwasa T, Sawada T, Sakiyama S . 1990 Carinogenesis 11: 75–80
Hiwasa T, Sawada T, Sakiyama S . 1996a J. Biol. Chem. 271: 9181–9184
Hiwasa T, Soeda C, Takanohashi S, Kobayashi H, Suzuki A, Ueyama T, Ike Y . 1996b Int. J. Oncol. 8: 125–129
Hiwasa T, Tanigawara C, Sakiyama S . 1987 Cancer Res 47: 953–959
Hollstein MC, Metcalf RA, Welsh JA, Montesano R, Harris CC . 1990 Proc. Natl. Acad. Sci. USA 87: 9958–9961
Houghton JA, Weiss KD, Williams LG, Torrance PM, Houghton PJ . 1986 Biochem. Pharmacol. 35: 1351–1358
Hsing A, Faller DV, Vaziri C . 2000 J. Biol. Chem. 275: 26024–26031
Kagawa S, Fujiwara T, Hizuta A, Yasuda T, Zhang WW, Roth JA, Tanaka N . 1997 Oncogene 15: 1903–1909
Knudsen ES, Wang JYJ . 1996 J. Biol. Chem. 271: 8313–8320
Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JYJ, Knudsen ES . 2000 Mol. Cell. Biol. 20: 7751–7763
Kobayashi S, Koide Y, Endo M, Isono K, Ochiai T . 1999 Am. J. Surg. 177: 497–502
Kubbutat MH, Jones SN, Vousden KH . 1997 Nature 387: 299–303
Lu Y, Yamagishi N, Yagi T, Takebe H . 1998 Oncogene 16: 705–712
Miyashita T, Reed JC . 1995 Cell 80: 293–299
Mosmann T . 1983 J. Immunol. Method. 65: 55–63
Nabeya Y, Loganzo Jr F, Maslak P, Lai L, De Oliveira AR, Schwartz GK, Blundell ML, Altorki NK, Kelsen DP, Albino AP . 1995 Int. J. Cancer. 64: 37–46
Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N . 2000a Science 288: 1053–1058
Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y . 2000b Cell 102: 849–862
Ohmori M, Nagai M, Tasaka T, Koeffer HP, Ribowol K, Takahara J . 1999 Am. J. Hematol. 62: 118–119
Oka M, Hirose K, Iizuka N, Aoyagi K, Yamamoto K, Abe T, Hazama S, Suzuki T . 1995 J. Interferon Cytokine Res. 15: 1005–1009
Okamoto K, Prives C . 1999 Oncogene 18: 4606–4615
Oki E, Maehara Y, Tokunaga E, Kakeji Y, Sugimachi K . 1999 Cancer Lett. 147: 157–162
Oren M . 1999 J. Biol. Chem. 274: 36031–36034
Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiwara T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R . 1995 Mol. Cell. Biol. 15: 3032–3040
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B . 1997 Nature 389: 300–305
Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KMW, Putnam JB, Schea R, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D . 1996 Nat. Med. 2: 985–991
Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, Yamatsuji T, Nisizaki M, Roth JA, Tanaka N . 2000 Oncogene 19: 726–736
Sherr CJ . 1996 Science 274: 1672–1677
Shimada H, Shimizu T, Ochiai T, Liu T-L, Sashiyama H, Nakamura A, Matsubara H, Gunji Y, Kobayashi S, Tagawa M, Sakiyama S, Hiwasa T . 2001 Surg. Today 31: 597–604
Shinoura N, Muramatsu Y, Nisimura M, Yoshida Y, Saito A, Yokoyama T, Furukawa T, Horii A, Hasimoto M, Asai A, Kirino T, Hamada H . 1999 Cancer Res. 59: 5521–5528
Sionov RV, Moallem E, Berger M, Kazaz A, Gerlitz O, Ben-Neriah Y, Oren M, Haupt Y . 1999 J. Biol. Chem. 274: 8371–8374
Sun P, Dong P, Dai K, Hannon GJ, Beach D . 1998 Science 282: 2270–2272
Takahashi K, Kanazawa H, Chan C-T, Hosono T, Takahara M, Sato K . 1990 Jpn. J. Oral. Maxillofac. Surg. 36: 307–316
Toyama T, Iwase H, Watson P, Muzik H, Saettler E, Magliocco A, DiFrancesco L, Forsyth P, Garkavtsev I, Kobayashi S, Riabowol K . 1999 Oncogene 18: 5187–5193
Tokunaga E, Maehara Y, Oki E, Kitamura K, Kakeji Y, Ohno S, Sugimachi K . 2000 Cancer Lett. 152: 15–22
Wu GS, Saftig P, Peters C, El-Deiry WS . 1998 Oncogene 16: 2177–2183
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D . 1993 Nature 366: 701–704
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M . 1991 Nature 352: 345–347
Zarkowska T, Mittnacht S . 1997 J. Biol. Chem. 272: 12738–12746
Zhang WW, Alemany R, Wang J, Koch PE, Ordonez NG, Roth JA . 1995 Hum. Gene Ther. 6: 155–164
Zhu J, Chen X . 2000 Mol. Cell. Biol. 20: 5602–5618
Acknowledgements
The authors thank Dr Toshiyoshi Fujiwara (Okayama University Medical School) for providing us with adenoviral vectors and also for excellent advice on preparation of the vectors. This work was partly supported by an Advanced Medicine Development Project from the Ministry of Education, Science, Sports and Culture of Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shimada, H., Liu, TL., Ochiai, T. et al. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33ING1 in T.Tn human esophageal carcinoma cells. Oncogene 21, 1208–1216 (2002). https://doi.org/10.1038/sj.onc.1205176
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205176
Keywords
This article is cited by
-
Analysis of patients with colorectal cancer shows a specific increase in serum anti-ING1 autoantibody levels
BMC Cancer (2023)
-
INGs are potential drug targets for cancer
Journal of Cancer Research and Clinical Oncology (2017)
-
Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams
Gene Therapy (2016)
-
ING1 induces apoptosis through direct effects at the mitochondria
Cell Death & Disease (2013)
-
ING1 and ING2: multifaceted tumor suppressor genes
Cellular and Molecular Life Sciences (2013)